Q2 2024 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2024-08-14 · accession 0000950123-24-008730
$135.0M
Reported value
11
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67080N101 | NUVB | Nuvation Bio | $38.8M | 28.7% | 13,275,884 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics | $37.8M | 28.0% | 2,355,904 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $22.2M | 16.4% | 2,461,319 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $10.2M | 7.52% | 1,076,357 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc | $8.7M | 6.44% | 653,225 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Holding | $5.4M | 4.03% | 159,846 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $4.6M | 3.41% | 843,750 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $3.7M | 2.75% | 2,249,123 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $2.0M | 1.47% | 1,788,160 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $1.3M | 0.96% | 251,270 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $382,587 | 0.28% | 321,502 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.